logo
logo

Leaps by Bayer Leads USD 17 Million Series B Financing in Biotech Company Azitra

Oct 15, 2020•over 4 years ago

Round Type

series b

Leverkusen

Description

Leaps by Bayer, the impact investment arm of Bayer AG, today announced a USD 8 million financial investment in US-based clinical-stage medical dermatology biotech company Azitra Inc. The partnership will focus on developing cutting-edge skin products using engineered and wild-type bacteria for biotherapeutic, over-the-counter (OTC) and cosmetic applications leveraging Azitra’s technology platform for both live therapeutic products (LBPs) and consumer programs. Existing investors, Bios Partners and Connecticut Innovations also participated in the round.

Company Information

Company

Azitra

Location

Leverkusen, North Rhine-Westphalia, Germany

About

Azitra, Inc. is a clinical-stage medical dermatology company that combines the power of the microbiome with cutting-edge genetic engineering to treat skin disease. The company was founded in 2014 by scientists from Yale University and works with world-leading scientists in dermatology, microbiology, and genetic engineering to advance its pharmaceutical programs to treat cancer therapy associated skin rashes, targeted orphan indications and atopic dermatitis.

FundzWatch™ Score

64
Medium Activity

Buyer Intent Analysis

Get personalized insights on buying likelihood